Antibody drug conjugates: lessons from 20 years of clinical experience (Q38979084)

8 September 2017

1 reference

title

Antibody drug conjugates: lessons from 20 years of clinical experience (English)

1 reference

8 September 2017

A W Tolcher

1

1 reference

8 September 2017

11 October 2016

1 reference

8 September 2017

1 reference

8 September 2017

27

1 reference

8 September 2017

12

1 reference

8 September 2017

2168-2172

1 reference

Antibody-drug conjugates--an emerging class of cancer treatment

8 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

Antibody-drug conjugates—a new wave of cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

Genetically engineered models have advantages over xenografts for preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

Vinorelbine (Navelbine) in the treatment of non-small-cell lung cancer: studies with single-agent therapy and in combination with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

Vinorelbine (Navelbine): a third-generation vinca alkaloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

Ocular toxicity and cancer chemotherapy. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

Linked-in: design and efficacy of antibody drug conjugates in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

Timeline: Chemotherapy and the war on cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

Characterization and Higher-Order Structure Assessment of an Interchain Cysteine-Based ADC: Impact of Drug Loading and Distribution on the Mechanism of Aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW424

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDW424

1 reference

8 September 2017

1 reference

PubMed ID

27733376